BETA: Please send your feedback!
NewLink Genetics
NLNK:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
About
Biotechnology
Founded 1999
NewLink Genetics Corp. is a clinical stage immuno-oncology company, which focuses on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. The company's products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189 and IDO Pathway Inhibitors. NewLink Genetics was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA.
website
Headquarters
Executives
| Name | Title | Gender |
| John B. Henneman, III | Chief Financial Officer, Secretary & Executive VP | Male |
| Thomas P. Monath, MD | Chief Scientific Officer | Male |
| Charles J. Link, MD | Chairman, Chief Executive & Scientific Officer | Male |
| Nicholas N. Vahanian, MD, MBA | President, Director & Chief Medical Officer | Male |
| Eugene P. Kennedy | Vice President-Clinical & Medical Affairs | Male |
| Eugene Sackett | Vice President-Human Resources | Male |
Mindful Investing Summary
NewLink Genetics - Competitors and Related Companies
How NewLink Genetics stacks up to its peers in the Biotechnology industry or with competing business segments.
NewLink Genetics
NLNK:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
SIGA Technologies
SIGA:NAS
Pharmaceuticals: Other
—
SMALL cap
(—)
—
since start of 2022
—
Sinovac Biotech
SVA:NAS
Biotechnology
—
SMALL cap
(—)
—
since start of 2022
—
Sarepta Therapeutics
SRPT:NAS
Biotechnology
—
MID cap
(—)
—
since start of 2022
—
Bristol-Myers Squibb
BMY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—
Eli Lilly
LLY:NYS
Pharmaceuticals: Major
—
MEGA cap
(—)
—
since start of 2022
—